Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Presentation TCT 2024

Coronary Microvascular Disease -- How Do We Move the Field Forward?

Presenter: Rasha Al-Lamee

October 30, 2024

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Conference News ESC 2024

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

Shelley Wood

September 03, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Conference News EuroPCR 2024

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

Caitlin E. Cox

May 15, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Podcast TCTMD Talking Points

The ORBITA-2 Trial

April 03, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Video

» Conference Wrap-Up

TCT 2024 Day 3 Wrap-Up

October 29, 2024

Video

» Interview

Beyond the Data: ORBITA-COSMIC

April 15, 2024

Partner Content

Optimizing Clinical Decision Making with the CathWorks FFRangio® System

March 19, 2024

Advertisement

Coronary Microvascular Disease -- How Do We Move the Field Forward?

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

The ORBITA-2 Trial

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

TCT 2024 Day 3 Wrap-Up

Beyond the Data: ORBITA-COSMIC

Optimizing Clinical Decision Making with the CathWorks FFRangio® System

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content